PMV Pharma reports 33% ORR for rezatapopt in TP53 Y220C tumors; NDA for ovarian cancer planned Q1 2027

PMV Pharmaceuticals, Inc.

Overall ORR 33% (32/97 evaluable patients) across 8 tumor types; median duration of response 6.2 months.
Ovarian cancer cohort: 43% ORR (19/44), median DOR 7.6 months, includes one confirmed complete response.
Safety profile manageable: most TRAEs Grade 1-2, no discontinuations due to Grade 3 AST/ALT elevations, 3.7% discontinuation rate.
FDA feedback supports NDA for platinum resistant/refractory ovarian cancer; plan to enroll 20-25 more patients by Q1 2026.
NDA submission for rezatapopt in ovarian cancer targeted for end of Q1 2027.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.